DeepMed Research

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

Phase 2

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Interventions: Drug: Pramlintide acetate

First Posted Date: 2002-09-05

Last Posted Date: 2015-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT00044707

Locations: 🇺🇸
ICSL-Clinical Studies, Fort Lauderdale, Florida, United States

Evaluation of the Effect of Pramlintide on Satiety and Food Intake

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1

Interventions: Drug: Pramlintide acetate
Drug: Placebo

First Posted Date: 2002-08-05

Last Posted Date: 2015-10-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 51

Registration Number: NCT00042601

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Placebo
Drug: Pramlintide acetate

First Posted Date: 2002-08-01

Last Posted Date: 2015-09-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 296

Registration Number: NCT00042458

Locations: 🇺🇸
Grand Rapids Associated Interns, Grand Rapids, Michigan, United States
🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸
Private Practice, Lufkin, Texas, United States

and more 26 locations

Evaluation of the Bioavailability of Pramlintide

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: Pramlintide acetate

First Posted Date: 2002-08-01

Last Posted Date: 2015-09-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 75

Registration Number: NCT00042471

Locations: 🇺🇸
New Orleans Center for Clinical Research, New Orleans, Louisiana, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States

and more 1 locations

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: AC2993
Drug: Placebo

First Posted Date: 2002-06-10

Last Posted Date: 2015-02-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 336

Registration Number: NCT00039013

Locations: 🇺🇸
Thomas Jefferson University Diabetes Research Center, Philadelphia, Pennsylvania, United States
🇺🇸
Philadelphia Health Associates, Philadelphia, Pennsylvania, United States
🇺🇸
St. Agnes Health Care, Baltimore, Maryland, United States

and more 124 locations

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Phase 3

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Interventions: Drug: AC2993
Drug: Placebo

First Posted Date: 2002-06-10

Last Posted Date: 2015-02-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 377

Registration Number: NCT00039026

Locations: 🇺🇸
ANA Ventures, LLC, Mesa, Arizona, United States
🇺🇸
Comprehensive Diabetes-Endocrine Medical Associates, Redwood City, California, United States
🇺🇸
St. Agnes Health Care, Baltimore, Maryland, United States

and more 120 locations

Reversal of Ventricular Remodeling With Toprol-XL

Phase 3

Completed

Conditions: Heart Failure, Congestive

First Posted Date: 2002-05-29

Last Posted Date: 2010-11-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 300

Registration Number: NCT00038077

Locations: 🇺🇸
Research Site, Farmington, Connecticut, United States

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent

Interventions: Drug: AC2993
Drug: Placebo

First Posted Date: 2002-05-08

Last Posted Date: 2015-02-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 734

Registration Number: NCT00035984

Locations: 🇺🇸
Diabetes and Endocrinology Specialists, Chesterfield, Missouri, United States
🇺🇸
Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 97 locations

CAFE Comparison of Atypicals in First Episode of Psychosis

Phase 3

Completed

Conditions: Schizophrenia
Psychotic Disorders
Mental Health
Mental Disorders

First Posted Date: 2002-05-03

Last Posted Date: 2013-01-04

Lead Sponsor: AstraZeneca

Registration Number: NCT00034892

Locations: 🇺🇸
Research Site, Dallas, Texas, United States

A Comparison of Seroquel vs. Risperidone in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2002-05-03

Last Posted Date: 2013-01-04

Lead Sponsor: AstraZeneca

Registration Number: NCT00034905

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy